Flag­ship’s gene edit­ing start­up Tessera cuts jobs as it shifts re­sources to clin­ic

Tessera Ther­a­peu­tics, Flag­ship’s ma­jor bet on what it calls gene writ­ing, is let­ting go 13% to 14% of its work­force, a spokesper­son con­firmed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.